Kenvue Inc. (NYSE:KVUE) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,007,097 shares of the company’s stock after selling 831 shares during the period. Chevy Chase Trust Holdings LLC owned 0.05% of Kenvue worth $24,150,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of KVUE. SRS Capital Advisors Inc. increased its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the period. Continuum Advisory LLC grew its position in Kenvue by 2,071.1% in the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock valued at $47,000 after buying an additional 1,864 shares during the last quarter. Clarity Asset Management Inc. acquired a new position in Kenvue in the 4th quarter valued at $45,000. SBI Securities Co. Ltd. purchased a new position in Kenvue during the 4th quarter worth $46,000. Finally, Versant Capital Management Inc raised its position in Kenvue by 77.9% during the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company’s stock worth $82,000 after buying an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $21.17 on Thursday. The stock has a fifty day moving average price of $22.93 and a 200 day moving average price of $22.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market cap of $40.62 billion, a PE ratio of 38.49, a P/E/G ratio of 3.29 and a beta of 0.98. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the previous year, the company posted $0.28 EPS. The business’s revenue was down 3.9% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.87%. Kenvue’s dividend payout ratio is presently 149.09%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays lifted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a report on Monday, May 12th. Citigroup reaffirmed a “neutral” rating on shares of Kenvue in a report on Friday, June 13th. UBS Group increased their target price on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target on the stock. Finally, Canaccord Genuity Group upped their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.